Search

Your search keyword '"Gorse, Geoffrey J."' showing total 23 results
Start Over Author "Gorse, Geoffrey J." Topic vaccination
23 results on '"Gorse, Geoffrey J."'

1. Protecting Healthcare Personnel in Outpatient Settings: The Influence of Mandatory Versus Nonmandatory Influenza Vaccination Policies on Workplace Absenteeism During Multiple Respiratory Virus Seasons.

Author

Frederick J, Brown AC, Cummings DA, Gaydos CA, Gibert CL, Gorse GJ, Los JG, Nyquist AC, Perl TM, Price CS, Radonovich LJ, Reich NG, Rodriguez-Barradas MC, Bessesen MT, and Simberkoff MS

Subjects
Absenteeism, Adult, Efficiency, Organizational, Female, Health Policy, Humans, Immunization Programs organization & administration, Immunization Programs statistics & numerical data, Male, Middle Aged, Seasons, United States epidemiology, Health Personnel statistics & numerical data, Infection Control methods, Influenza, Human epidemiology, Influenza, Human prevention & control, Mandatory Programs organization & administration, Mandatory Programs statistics & numerical data, Vaccination methods, Vaccination statistics & numerical data
Abstract

OBJECTIVE To determine the effect of mandatory and nonmandatory influenza vaccination policies on vaccination rates and symptomatic absenteeism among healthcare personnel (HCP). DESIGN Retrospective observational cohort study. SETTING This study took place at 3 university medical centers with mandatory influenza vaccination policies and 4 Veterans Affairs (VA) healthcare systems with nonmandatory influenza vaccination policies. PARTICIPANTS The study included 2,304 outpatient HCP at mandatory vaccination sites and 1,759 outpatient HCP at nonmandatory vaccination sites. METHODS To determine the incidence and duration of absenteeism in outpatient settings, HCP participating in the Respiratory Protection Effectiveness Clinical Trial at both mandatory and nonmandatory vaccination sites over 3 viral respiratory illness (VRI) seasons (2012-2015) reported their influenza vaccination status and symptomatic days absent from work weekly throughout a 12-week period during the peak VRI season each year. The adjusted effects of vaccination and other modulating factors on absenteeism rates were estimated using multivariable regression models. RESULTS The proportion of participants who received influenza vaccination was lower each year at nonmandatory than at mandatory vaccination sites (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.07-0.11). Among HCP who reported at least 1 sick day, vaccinated HCP had lower symptomatic days absent compared to unvaccinated HCP (OR for 2012-2013 and 2013-2014, 0.82; 95% CI, 0.72-0.93; OR for 2014-2015, 0.81; 95% CI, 0.69-0.95). CONCLUSIONS These data suggest that mandatory HCP influenza vaccination policies increase influenza vaccination rates and that HCP symptomatic absenteeism diminishes as rates of influenza vaccination increase. These findings should be considered in formulating HCP influenza vaccination policies. Infect Control Hosp Epidemiol 2018;39:452-461.

Published
2018
Full Text
View/download PDF

2. Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Author

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, and Corey L

Subjects
AIDS Vaccines administration & dosage, Adolescent, Adult, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assay, Female, HIV Antibodies blood, Humans, Interferon-gamma metabolism, Male, Middle Aged, Placebos administration & dosage, Treatment Outcome, Young Adult, AIDS Vaccines adverse effects, AIDS Vaccines immunology, Acquired Immunodeficiency Syndrome prevention & control, HIV-1 immunology, Vaccination adverse effects, Vaccination methods
Abstract

Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVAC-HIV (vCP1452) alone, or 3 groups of ALVAC-HIV (vCP1452) followed by ALVAC-HIV (vCP1452) plus LIPO-5 (250, 750, and 2,500 μg). Only 73/174 participants (42%) received all four vaccinations due to a study halt related to myelitis. There were no significant differences in systemic reactions between groups or in local reactogenicity between groups receiving ALVAC-HIV (vCP1452). Significant differences in local reactogenicity occurred between groups receiving LIPO-5 (P ≤ 0.05). Gag and Env antibodies were undetectable by ELISA 2 weeks after the fourth vaccination for all but one recipient. Antibodies to Gag and Env were present in 32% and 24% of recipients of ALVAC-HIV (vCP1452) alone and in 47% and 35% of ALVAC-HIV (vCP1452)+LIPO recipients, respectively. Coadministration of LIPO-5 did not significantly increase the response rate compared to ALVAC-HIV (vCP1452) alone, nor was there a significant relationship between dose and antibody responses among ALVAC-HIV (vCP1452)+LIPO groups. Over 90% of study participants had no positive gamma interferon (IFN-γ) enzyme-linked immunosorbent spot assay (ELISpot) responses to any peptide pool at any time point. The study was halted due to a case of myelitis possibly related to the LIPO-5 vaccine; this case of myelitis remains an isolated event. In general, there was no appreciable cell-mediated immunity detected in response to the vaccines used in this study, and antibody responses were limited. The clinical trial is registered on ClinicalTrials.gov with registry number NCT00076063., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)

Published
2014
Full Text
View/download PDF

4. Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines—Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High-Risk Elderly Individuals

Author

Falsey, Ann R., Walsh, Edward E., Capellan, Jose, Gravenstein, Stefan, Zambon, Maria, Yau, Eddy, Gorse, Geoffrey J., Edelman, Robert, Hayden, Frederick G., McElhaney, Janet E., Neuzil, Kathleen M., Nichol, Kristen L., Simões, Eric A. F., Wright, Peter F., and Sales, Valérie M.-P.

Published
2008
Full Text
View/download PDF

6. Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing Either HIV-1 Genes or the Gene for Rabies Virus G Protein

Author

The National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, Wright, Peter F., Mestecky, Jiri, McElrath, M. Juliana, Keefer, Michael C., Gorse, Geoffrey J., Goepfert, Paul A., Moldoveanu, Zina, Schwartz, David, Spearman, Paul W., El Habib, Raphaelle, Spring, Michele D., Zhu, Yuwei, Smith, Carol, Flores, Jorge, and Weinhold, Kent J.

Published
2004

8. Safety and Immunogenicity of a Canarypox-Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher- and Lower-Risk Volunteers

Author

National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET), Belshe, Robert B., Stevens, Cladd, Gorse, Geoffrey J., Buchbinder, Susan, Weinhold, Kent, Sheppard, Haynes, Stablein, Donald, Self, Steve, McNamara, James, Frey, Sharon, Flores, Jorge, Excler, Jean Louis, Klein, Michel, El Habib, Raphaelle, Duliege, Anne-Marie, Harro, Clayton, Corey, Lawrence, Keefer, Michael, Mulligan, Mark, Wright, Peter, Celum, Connie, Judson, Frank, Mayer, Kenneth, McKirnan, David, Marmor, Michael, and Woody, George

Published
2001

10. A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgpl20 Elicits Broad and Durable CD8⁺ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

Author

NIAID AIDS Vaccine Evaluation Group, Evans, Thomas G., Keefer, Michael C., Weinhold, Kent J., Wolff, Mark, Montefiori, David, Gorse, Geoffrey J., Graham, Barney S., McElrath, M. Juliana, Clements-Mann, Mary Lou, Mulligan, Mark J., Fast, Patricia, Walker, Mary Clare, Excler, Jean-Louis, Duliege, Ann-Marie, and Tartaglia, James

Published
1999

11. Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing $HIV-1_mn$ gpl20, $HIV-1_SF2$ Recombinant gp120, or Both Vaccines in Seronegative Adults

Author

NIAID AIDS Vaccine Evaluation Group, Clements-Mann, Mary Lou, Weinhold, Kent, Matthews, Thomas J., Graham, Barney S., Gorse, Geoffrey J., Keefer, Michael C., McElrath, M. Juliana, Hsieh, Ray-Hahn, Mestecky, Jiri, Zolla-Pazner, Susan, Mascola, John, Schwartz, David, Siliciano, Robert, Corey, Lawrence, Wright, Peter F., Belshe, Robert, Dolin, Raphael, Jackson, Susan, Xu, Serena, Fast, Patricia, Walker, Mary Clare, Stablein, Don, Excler, Jean-Louis, Tartaglia, James, Duliege, Anne-Marie, Sinangil, Faruk, and Paoletti, Enzo

Published
1998

12. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines

Author

AIDS Vaccine Evaluation Group, Correlates of HIV Immune Protection Group, Graham, Barney S., McElrath, M. Juliana, Connor, Ruth I., Schwartz, David H., Gorse, Geoffrey J., Keefer, Michael C., Mulligan, Mark J., Matthews, Thomas J., Wolinsky, Steven M., Montefiori, David C., Vermund, Sten H., Lambert, John S., Corey, Lawrence, Belshe, Robert B., Dolin, Raphael, Wright, Peter F., Korber, Bette T., Wolff, Mark C., and Fast, Patricia E.

Published
1998

13. Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1

Author

Mascola, John R., Snyder, Stuart W., Weislow, Owen S., Belay, Seifu M., Belshe, Robert B., Schwartz, David H., Clements, Mary Lou, Dolin, Raphael, Graham, Barney S., Gorse, Geoffrey J., Keefer, Michael C., McElrath, M. Juliana, Walker, Mary Clare, Wagner, Kenneth F., McNeil, John G., McCutchan, Francine E., and Burke, Donald S.

Published
1996

16. Determinants of Antibody Response after Recombinant gp160 Boosting in Vaccinia-Naive Volunteers Primed with gp160-Recombinant Vaccinia Virus

Author

National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network, Graham, Barney S., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., McElrath, M. Juliana, Matthews, Thomas J., Wright, Peter F., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Corey, Lawrence, Bolognesi, Dani P., Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, and Smith, Gale E.

Published
1994

18. Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial

Author

AIDS Vaccine Clinical Trails Network, Graham, Barney S., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Corey, Lawrence, Wright, Peter F., Gorse, Geoffrey J., Midthun, Karen, Keefer, Michael C., Roberts, Norbert J., Schwartz, David H., Agosti, Jan M., Fernie, Bruce F., Stablein, Donald M., Montefiori, David C., Lambert, John S., Esterlitz, Joy R., Lawrence, Dale N., and Koff, Wayne C.

Published
1992

19. Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gpl60 Recombinant Vaccinia and Boosting with rgpl60 in Vaccinia-Naive Adults

Author

NIAID AIDS Vaccne Clinical Trails Network, Graham, Barney S., Matthews, Thomas J., Belshe, Robert B., Clements, Mary Lou, Dolin, Raphael, Wright, Peter F., Gorse, Geoffrey J., Schwartz, David H., Keefer, Michael C., Bolognesi, Dani P., Corey, Lawrence, Stablein, Donald M., Esterlitz, Joy R., Hu, Shiu-Lok, Smith, Gale E., Fast, Patricia E., and Koff, Wayne C.

Published
1993

21. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial

Author

Gorse, Geoffrey J., Keitel, Wendy, Keyserling, Harry, Taylor, David N., Lock, Michael, Alves, Katia, Kenner, Julie, Deans, Lynne, and Gurwith, Marc

Subjects
*ANTHRAX, *VACCINATION, *IMMUNIZATION, *INJECTIONS
Abstract

Summary: Background: We report the results of a phase I dose escalation, safety and immunogenicity trial of a new recombinant protective antigen (rPA102) anthrax vaccine. Methods: Hundred healthy volunteers were randomized in a 4:1 ratio to receive intramuscular doses of rPA102 in the following formulations: 5, 25, 50, or 75μg of rPA102 in 82.5μg aluminum hydroxide adjuvant at 0, 4, and 8 weeks; or the US licensed Anthrax Vaccine Adsorbed (AVA) at weeks 0 and 4. Findings: Local reactogenicity (mostly pain) was more common with AVA than with rPA102 following the first (94.7% versus 44.4%; p <0.001) and the second (84.2% versus 35.4%; p <0.001) vaccinations. Systemic reactogenicity (mostly headache) was more common among rPA102 vaccinees, but only following the first vaccination (49.4% versus 15.8%; p =0.025). A dose-response relationship for anti-PA antibodies was present after the 2nd and 3rd vaccinations. Two weeks following the 2nd vaccination, the geometric mean titers (GMT) for lethal toxin neutralization activity (TNA), for the 5, 25, 50 and 75μg rPA102 and AVA groups were 38.6, 75.4, 373.9, 515.3, and 855.2, respectively. The geometric mean concentrations (GMC) measured by anti-PA IgG ELISA were 3.7, 11.5, 25.9, 44.1, and 171.6, respectively. Two weeks following the 3rd vaccination, TNA GMTs for the four rPA102 groups, were: 134.7, 719.7, 2116.6, 2422.4; and ELISA GMCs were: 22.9, 104.7, 196.4, and 262.6, respectively. Interpretation: No clinically serious or dose-related toxicity or reactogenicity was observed. The TNA response after two injections of the 75μg dose of rPA102 was similar to the response after two injections of AVA. The third rPA102 vaccination substantially increased the antibody response. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

22. Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults.

Author

Nichol, Kristin L., Mendelman, Paul M., Mallon, Kenneth P., Jackson, Lisa A., Gorse, Geoffrey J., Belshe, Robert B., Glezen, W. Paul, and Wittes, Janet

Subjects
INFLUENZA vaccines, RESPIRATORY infections, VIRAL vaccines, VACCINATION
Abstract

Reports on the effectiveness of live, attenuated influenza virus (LAIV) vaccines and the economic and medical implications. Objective; Design; Setting; Participants; Intervention; Main outcome measures; Results; Conclusion.

Published
1999
Full Text
View/download PDF

23. Recruitment and Baseline Epidemiologic Profile of Participants in the First Phase 3 HIV Vaccine Efficacy Trial.

Author

Harro, Clayton D., Judson, Franklyn N., Gorse, Geoffrey J., Mayer, Kenneth H., Kostman, Jay R., Brown, Stephen I., Koblin, Beryl, Marmor, Michael, Bartholow, Bradford N., and Popovic, Vladimir

Subjects
*HIV infections, *AIDS, *AIDS vaccines, *PREVENTIVE medicine, *VACCINATION
Abstract

Describes the recruitment and baseline epidemiologic characteristics of volunteers in the first phase 3 placebo-controlled trial of recombinant gp120 HIV vaccine. Medical history of participants in the study; Recruitment strategies; Demographics; Risk factors; Determination of HIV status by standard HIV-1 antibody assays; HIV-1 nucleic acid test conducted to determine seronegative and viremic HIV infection at enrollment.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results